APCCC 2024 | The role of adjuvant therapy after radical prostatectomy in prostate cancer

Jason Efstathiou, MD, DPhil, Harvard Medical School, Boston, MA, discusses the selection and management of patients for adjuvant radiotherapy post-radical prostatectomy. Determining the optimal PSA for salvage therapy is needed, and additional research is required to elucidate what level of PSA is deemed undetectable. Prof. Efstathiou additionally highlights trials such as RADICALS-RT (NCT00541047), RADICALS-HD (ISRCTN40814031), and INNOVATE (NCT04134260), which all aim to assess the role of adjuvant therapy in this setting, as well as evaluate novel biomarkers. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.